Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T75440 Target Info
Target Name Translocator protein (TSPO)
Synonyms Peripheral-type benzodiazepine receptor; Peripheral benzodiazepine receptor; PKBS; PBR; Mitochondrial benzodiazepine receptor; MBR; BZRP
Target Type Successful Target
Gene Name TSPO
Biochemical Class Cholesterol/porphyrin uptake translocator
UniProt ID
TSPO_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2015162615
Title Quinazoline Scaffold Based Compounds, Pharmaceutical Compositions and Methods of Use Thereof.
Abstract The present invention relates to novel heterocyclic compounds based on a quinazoline scaffold of formula (I), which bind effectively to the mitochondrial translocator protein (TSPO), and counteract cell death processes. These compounds can also stimulate neuronal differentiation. The present invention further relates to pharmaceutical compositions including such compounds, and methods of using these compounds for the prevention and treatment of brain damage resulting from brain injury, especially secondary brain damage due to traumatic brain injury (TBI). The compounds of the invention are also useful in preventing, treating, and curing brain damage due to neurodegenerative diseases, including underlying and associated pathological and mental disorders. The compounds can also be used to prevent and treat brain damage due to infection, toxic challenges, and excessive drug use, e.g., recreational, over the counter, or prescription drugs. These compounds can also prevent heart failure, for example associated with brain injuries and brain diseases.
Applicant(s) Technion Research & Development Foundation Limited
Representative Drug(s) D0S2SS Drug Info Ki = 2.5 nM Click to Show More [1]
2 D0TP7S Drug Info Ki = 2.5 nM [1]
3 D09JTT Drug Info Ki = 60 nM [1]
4 D0K3ZB Drug Info Ki = 60 nM [1]
5 D02UMS Drug Info Ki = 600 nM [1]
Patent ID WO2015040148
Title Carbazole Compounds for In Vivo Imaging.
Abstract The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.
Applicant(s) Ge Healthcare Limited
Representative Drug(s) D00UDJ Drug Info Ki = 3 nM Click to Show More [2]
2 D01PXI Drug Info Ki = 4 nM [2]
3 D0B3RK Drug Info Ki = 24 nM [2]
Patent ID WO2012041953
Title In Vivo Imaging Method for Cancer.
Abstract The present invention provides a method useful in the diagnosis and monitoring of cancer wherein there is an abnormal expression of PBR. The method of the invention is particularly useful in evaluating the severity of the cancer, e.g. PBR expression correlates with cell proliferation rates, metastatic potential, tumour aggressiveness, malignancy progression. The method of the invention can therefore be applied in the determination of likely disease progression and in making an associated prognosis. Furthermore, the method of the invention can find use in determining the likely success of certain therapeutic approaches, or in the evaluation of the efficacy of certain proposed new treatments.
Applicant(s) Ge Healthcare Limited
Representative Drug(s) D04SWU Drug Info Ki = 0.73 nM Click to Show More [2]
2 D0L5EG Drug Info Ki = 0.87 nM [2]
3 D02VRI Drug Info Ki = 1.3 nM [2]
4 D0E6TQ Drug Info Ki = 1.5 nM [2]
5 D0RT5D Drug Info Ki = 1.7 nM [2]
6 D0TQ8V Drug Info Ki = 1.9 nM [2]
7 D0K3QX Drug Info Ki = 3.8 nM [2]
8 D0Q5JO Drug Info Ki = 4 nM [2]
9 D0R0OA Drug Info Ki = 5.4 nM [2]
10 D0NF3Y Drug Info Ki = 7.6 nM [2]
11 D0EI2Q Drug Info Ki = 18 nM [2]
Patent ID WO2010106166
Title Radiolabelled pyridinyl derivatives for in-vivo imaging.
Abstract The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.
Applicant(s) GE HEALTHCARE LIMITED
Representative Drug(s) D0A5RG Drug Info Ki = 0.056 nM Click to Show More [1]
2 D0TB2L Drug Info Ki = 2.6 nM [1]
3 D06HIJ Drug Info Ki = 3.6 nM [1]
4 D0IY5H Drug Info Ki = 4.2 nM [1]
Patent ID WO2010037851
Title Indole Derivatives Suitable for Imaging Neuroinflammation.
Abstract The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.
Applicant(s) Ge Healthcare Limited
Representative Drug(s) D0U0IH Drug Info Ki = 0.68 nM [2]
Patent ID WO2010015340
Title Daa-Pyridine As Peripheral Benzodiazepine Receptor Ligand for Diagnostic Imaging and Pharmaceutical Treatment.
Abstract This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for therapy and diagnostic imaging by positron emission tomography (PET).
Applicant(s) Bayer Schering Pharma Aktiengesellschaft Lehmann
Representative Drug(s) D0TB2L Drug Info Ki = 2.6 nM Click to Show More [1]
2 D06HIJ Drug Info Ki = 3.6 nM [1]
3 D0IY5H Drug Info Ki = 4.2 nM [1]
Patent ID WO1999056736
Title Apoptosis-Inducing Compounds.
Abstract The present invention relates to pyrrolobenzoxazepines, pyrrolobenzthiazepines and related compounds having the ability to induce apoptosis, to pharmaceutical compositions comprising these compounds and to their use as anti-tumour agents.
Applicant(s) The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen
Representative Drug(s) D0GN5R Drug Info IC50 = 0.94 nM; Ki = 0.36 nM Click to Show More [1]
2 D05GJL Drug Info IC50 = 1.3 nM; Ki = 0.52 nM [1]
3 D0G7HK Drug Info IC50 = 1.3 nM; Ki = 0.51 nM [1]
4 D0GY0E Drug Info IC50 = 2.3 nM; Ki = 0.91 nM [1]
5 D08XOA Drug Info IC50 = 3.8 nM; Ki = 1.5 nM [1]
6 D0O8DG Drug Info IC50 = 4 nM; Ki = 1.8 nM [1]
7 D03ENW Drug Info IC50 = 5.1 nM; Ki = 2 nM [1]
Patent ID WO1999006353
Title Aryloxyaniline Derivatives.
Abstract Aryloxyaniline derivatives represented by the general formula (I), wherein Ar1 and Ar2represent each a substituted or unsubstituted phenyl, pyridyl, or naphthyl group; R1 represents a hydrogen atom, an alkyl group or the like; X1 represents a hydrogen atom, an alkyl group or the like; and Y1 represents a branched or unbranched 1-6 C alkylene group or a single bond, or pharmaceutically acceptable salts thereof. The derivatives can provide medicines having high affinity for MDR exhibiting therapeutic and prophylactic effects on anxiety and associated diseases, depression, and the like.
Applicant(s) Taisho Pharmaceutical Co., Ltd
Representative Drug(s) D04JEH Drug Info IC50 = 0.28 nM Click to Show More [1]
2 D0FR9I Drug Info IC50 = 0.92 nM; Ki = 2.8 nM [1]
Patent ID WO1993011771
Title Use of Peripheral-Type Benzodiazepine Sites for Treatment of Cns Trauma or Disease.
Abstract It is a purpose of this invention to provide a means of treating various central nervous system (CNS) injuries to prevent or minimize damage to the CNS. A novel use has been found for some previously known compounds which are inhibitory agonists of the peripheral-type BZ receptors. It is another purpose of this invention to provide a means of speeding the recovery of tissue damaged through injury to the CNS. The above described inhibitory agonists of the peripheral-type BZ receptors are useful for this purpose, and provide an easily administrable medication. Additionally, a means is provided for screening for new compounds which will act as inhibitory agonists of the peripheral-type BZ receptors and therefore which can be used for treating CNS injuries and for speeding the recovery of tissue damaged through such injuries.
Applicant(s) Cocensys, Inc
Representative Drug(s) D0FF5C Drug Info IC50 = 0.11 nM Click to Show More [1]
2 D0PE1K Drug Info IC50 = 0.2 nM [1]
3 D06WUT Drug Info IC50 = 4.6 nM [1]
4 D0OB0Q Drug Info IC50 = 9.8 nM [1]
5 D01KPW Drug Info Ki = 28 nM [1]
6 D07KTM Drug Info IC50 = 1500 nM [1]
7 D0AW8P Drug Info IC50 = 10000 nM [1]
8 D0N9DS Drug Info N.A. [1]
9 D0R2XX Drug Info N.A. [1]
Patent ID WO2014138791
Title Transgenic Non-Human organisms with Non-Functional Tspo Genes.
Abstract The present invention relates to transgenic animal models. Specifically, the present invention relates to transgenic animal models for applications associated with TSPO-related normal physiology, diseases and disorders. The present invention features a transgenic nonhuman animal comprising cells with at least one copy of a non-functional, endogenous TSPO gene. Also disclosed are compounds for investigating or modulating TSPO-related functions.
Applicant(s) Australian Nuclear Science and Technology Organization the University of Sydney
Representative Drug(s) D0HS8T Drug Info Ki = 16 nM Click to Show More [1]
2 D01WQX Drug Info N.A. [1]
Patent ID WO2015113991
Title Treatment of Degenerations and Light-Induced Damage To The Retina.
Abstract The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, to be used in the prevention or treatment of light-induced damage and/or a degeneration of the retina in a patient.
Applicant(s) Biocodex
Representative Drug(s) D08ZHA Drug Info N.A. Click to Show More [2]
2 D0JN7L Drug Info N.A. [2]
Patent ID WO2005080334
Title Novel Heterocyclic Compound.
Abstract Disclosed is a drug having a high affinity for benzodiazepine &ohgr;3 receptors which contains, for example, a compound represented by the formula (1) below as an active constituent and has curative and preventive effects on anxiety and depression. (1) [In the formula, R1 and R2 independently represent a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group or the like; R3 and R4 independently represent a hydrogen atom, an optionally substituted alkyl group or the like; R5, R6, R7 and R8 independently represent a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group or the like; and X represents an oxygen atom, a sulfur atom, NR10 or the like (wherein R10 represents a hydrogen atom, an optionally substituted alkyl group or the like).].
Representative Drug(s) D08DPU Drug Info N.A. Click to Show More [1]
2 D0AC4P Drug Info N.A. [1]
Patent ID WO2015190568
Title Medicine for Preventing and/or Treating Stress-Induced Diseases.
Abstract The present invention relates to a medicine for preventing and/or treating stress-induced diseases, said medicine being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[gama-carboline-4,1'-cyclopropane] is administered at such a specific dose that a brain TSPO occupancy required for the development of the pharmacological activity of the medicine can be obtained.
Applicant(s) Ono Pharmaceutical Co., Ltd
Representative Drug(s) D09GSO Drug Info Ki = 0.08 nM [2]
Patent ID WO2015037774
Title [18F]Fluoromethyl Group-Introduced Radiotracer for Positron Emission Tomography for Targeting Brain Neuroinflammation, Synthesis Thereof, and Method for Evaluating Biological Results Using Same.
Abstract The present invention relates to an [18F]fluoromethyl group-introduced radiotracer for positron emission tomography for targeting brain neuroinflammation, a synthesis thereof, and a method for evaluat.
Applicant(s) Bio Imaging Korea Co., Ltd
Representative Drug(s) D0E2XN Drug Info Ki = 8.3 nM [1]
Patent ID WO2014164678
Title Translocator Protein Imaging Agents; Methods of Manufacture, and Methods of Use Thereof.
Abstract Radiolabeled 4-phenylquinazoline-2-carboxamides useful as imaging agents for positron emission tomography of translocator protein (TSPO) are described. Methods of detecting TSPO and neuroinflammation using the compounds are described. Also disclosed are radiolabeling methods for selected compounds.
Applicant(s) The United States of America, As Presented By the Secretary, Department of Health and Human Services
Patent ID WO2013076646
Title A New Diaza-Benzofluoranthene Derivative As Drug.
Abstract The present invention relates to a new 16-tetrazolyl-eburnamenine of formula (I) or pharmaceutically acceptable salt thereof and/or hydrates and/or solvates thereof. The invention also relates to the pharmaceutical compositions containing the compound of formula (I) or hydrates or solvates thereof as active ingredient. The invention also relates to the synthesis of compounds of formula (I), and the chemical and pharmaceutical manufacture of medicaments containing these compounds, as well as the methods of treatment of mammals - including human - with these compounds. There is still further provided methods for the treatment of neurological, neurodegenerative and psychiatric diseases or conditions as well as comprising the step of administering to human, in need of such treatment and/or prophylaxis a pharmaceutical composition comprising a therapeutically effective amount of compound of formula (I) or pharmaceutically acceptable salts thereof alone or together with at least one and a pharmaceutically acceptable carrier and/or diluent.
Applicant(s) Richter Gedeon Nyrt
Representative Drug(s) D0AP1F Drug Info N.A. [2]
Patent ID WO2015040151
Title S-Enantiomer of Tetracyclic Indole Derivative As Pbr Ligands.
Abstract The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invent ion, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.
Applicant(s) Ge Healthcare Limited
Patent ID WO2015040087
Title Macrophage Imaging.
Abstract The present invention concerns in vivo imaging and in particular in vivo imaging of activated macrophages. An indole-based in vivo imaging agent labelled with 18F is provided that binds with high affinity to translocator protein (TSPO). Other aspects of the invention include a method of diagnosis and a method of therapy monitoring which comprise the imaging method. In addition, the invention provides the use of the TSPO imaging agent in the methods of the invention.
Applicant(s) Ge Healthcare Limited
Patent ID WO2007103162
Title Structure Based Drug Design of Steroidogenesis Inhibitors.
Abstract Steroidogenesis begins with the transfer of free cholesterol from intracellular stores into mitochondria. The peripheral-type benzodiazepine receptor (PBR) and steroidogenic acute regulatory protein (StAR) function in this process, functioning together to shuttle cholesterol from outside the mitochondria to the inner mitochondrial membrane. The present invention provides methods of using structure-based drug design to identify peptide and substituted steroid compounds that can inhibit the activity of PBR and StAR via interaction with their cholesterol-binding domains. These approaches facilitated the identification of a number of inhibitory ligands that decrease steroid biosynthesis.
Applicant(s) Samaritan Pharmaceuticals, Inc
Patent ID WO2007057705
Title Tetracyclic Indole Derivatives As In Vivo Imaging Agents and Having Peripheralbenzodiazepine Receptor Affinity (Pbr).
Abstract The present invention provides novel tetracyclic indole compounds of Formula (I) either as in vivo imaging agents or as therapeutic agents. A method for the preparation of the in vivo imaging agent compound is also provided by the invention, as well as a precursor for use in said method. Pharmaceutical compositions comprising the compounds of the invention are additionally provided. Where the pharmaceutical composition comprises a compound suitable for in vivo imaging, a kit is provided for the preparation of the pharmaceutical composition. In a further aspect, use of the compound for in vivo imaging or treatment of conditions associated with PBR is provided.
Applicant(s) Hammersmith Imanet Ltd
Patent ID WO2006068164
Title Tricyclic Compound and Use Thereof.
Abstract Disclosed is a compound represented by the following general formula (I): (I) (wherein all the symbols are as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof, or a p.
Applicant(s) Ono Pharmaceutical Co., Ltd
Patent ID WO2000044384
Title Use of Pyridazino[4,5-B]Indole-1-Acetamide Derivatives for Preparing Medicines for Treating Diseases Related To The Dysfunction of Peripheral Benzodiazepin Receptors.
Abstract The invention concerns the use of a compound of general formula (I) wherein: X represents a halogen atom; Y represents one or several atoms or groups selected among hydrogen, halogens and hydroxy, methyl, methoxy and nitro groups; R1 represents a C1-C4 alkyl group; R2 and R3 represent each a hydrogen atom or a C1-C4 alkyl group, or R2 and R3 together form with the nitrogen atom bearing them, a pyrrolidinyl, piperidinyl or morpholinyl group, for preparing a medicine for preventing or treating diseases and disorders related to the peripheral benzodiazepin receptor.
Applicant(s) Sanofi Synthelabo
Patent ID WO2010109007
Title Indole Derivatives.
United States Patent and Trademark Office (USPTO)
Patent ID US5998624
Title Haloisoquinoline Carboxamide.
Representative Drug(s) D0I6CF Drug Info Ki = 0.26 nM Click to Show More [1]
2 D0EY2Q Drug Info Ki = 1.3 nM [1]
3 D0CL2E Drug Info Ki = 63 nM [1]
Patent ID US20130203754
Title 2-Aryl Imidazo[1,2-A]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof.
Representative Drug(s) D0EG4F Drug Info Ki = 3 nM Click to Show More [1]
2 D0PO3M Drug Info Ki = 7.2 nM [1]
3 D0MR8D Drug Info Ki = 9.3 nM [1]
4 D0K4UF Drug Info Ki = 11 nM [1]
5 D00EBN Drug Info Ki = 39 nM [1]
6 D06PPD Drug Info Ki = 49 nM [1]
Patent ID US20120189548
Title 2-Arylpyrazolo[L,5-Alpha]Pyrimidin-3-Yl Acetamide Derivatives As Ligands for Translocator Protein (18 Kda).
Representative Drug(s) D01LOJ Drug Info Ki = 4.7 nM Click to Show More [1]
2 D0LB3J Drug Info Ki = 7 nM [1]
Patent ID US20110142757
Title ANovel Compounds and Their Uses In Diagnosis.
Representative Drug(s) D0KZ5O Drug Info Ki = 12 nM Click to Show More [1]
2 D0G5FS Drug Info Ki = 51 nM [1]
Patent ID US20110044898
Title Translocator Protein Ligands.
Representative Drug(s) D04ESE Drug Info Ki = 0.45 nM Click to Show More [1]
2 D08RTY Drug Info Ki = 0.46 nM [1]
3 D07RWQ Drug Info Ki = 0.97 nM [1]
4 D0M9PB Drug Info Ki = 1.6 nM [1]
5 D09AKT Drug Info Ki = 2.4 nM [1]
6 D0P1TH Drug Info Ki = 2.6 nM [1]
7 D0K3MV Drug Info Ki = 11 nM [1]
Patent ID US20140301947
Title Methods To Predict Binding Affinity of Tspo Imaging Agents To Tspo.
Representative Drug(s) D0FR9I Drug Info IC50 = 0.92 nM; Ki = 2.8 nM Click to Show More [2]
2 D0H2RG Drug Info Ki = 2.4 nM [2]
3 D01LOJ Drug Info Ki = 4.7 nM [2]
4 D08RNV Drug Info Ki = 8.6 nM [2]
5 D0HS8T Drug Info Ki = 16 nM [2]
6 D01KPW Drug Info Ki = 28 nM [2]
7 D01DWN Drug Info N.A. [2]
Patent ID US20090317328
Title Tricyclic Oxazepines As In Vivo Imaging Compounds.
Representative Drug(s) D0K4VT Drug Info N.A. [1]
Patent ID US8338410
Title Neuroprotective Compounds and Pharmaceutical Compositions Comprising Them.
Applicant(s) Biocodex
Representative Drug(s) D07RRL Drug Info N.A. Click to Show More [2]
2 D0LE6B Drug Info N.A. [2]
Patent ID US20120244073
Title Aryloxyanilide Imaging Agents.
Representative Drug(s) D01BXA Drug Info N.A. Click to Show More [1]
2 D03PTY Drug Info N.A. [1]
Patent ID US8541428
Title Heterocyclic Derivatives, Pharmaceutical Compositions and Methods of Use Thereof.
Representative Drug(s) D06RNU Drug Info Ki = 600 nM [1]
Patent ID US8338488
Title Use of At Least One Oxime Derivative of 3,5-Seco-4-Nor-Cholestane As Antioxidants.
Representative Drug(s) D09GSO Drug Info Ki = 0.08 nM [2]
Patent ID US20130177501
Title In Vivo Imaging Method of Mood Disorders.
Representative Drug(s) D0L5EG Drug Info Ki = 0.87 nM [2]
Patent ID US20026372740
Title 2-Aryl-8-Oxodihydropurine Derivative, Process for The Producing The Same, Medicinal Compositions Containing The Same, and Intermediates Thereof.
Applicant(s) Dainippon Pharmaceutical Co., Ltd
Representative Drug(s) D0RH7L Drug Info N.A. [1]
Patent ID US8110569
Title Enantiomerically Pure S-Etifoxine, Pharmaceutical Compositions Thereof and Methods of Their Use.
Representative Drug(s) D0LE6B Drug Info N.A. [2]
Patent ID US6372740
Title 2-Aryl-8-Oxodihydropurine Derivative, Process for The Producing The Same, Medicinal Compositions Containing The Same, and Intermediates Thereof.
Representative Drug(s) D0N5LW Drug Info N.A. [1]
Patent ID US20110212025
Title Tspo-Targeting Compounds and Uses Thereof.
Representative Drug(s) D05ZAV Drug Info N.A. [1]
Patent ID US20100029658
Title Heterocyclic Derivatives, Pharmaceutical Compositions and Methods of Use Thereof.
Representative Drug(s) D0R2XX Drug Info N.A. [1]
Patent ID US20120039816
Title Use of 7-Chloro-N,N,5-Trimethyl-4-Oxo-3-Phenyl-3,5-Dihydro-4H-Pyridazino[4,5-B] Indole-1-Acetamide As A Biomarker of Peripheral Benzodiazepine Receptor Levels.
Intellectual Property Office in India (IP India)
Patent ID IN2012CH03232
Title Process for The Preparation of Etifoxine Hydrochloride.
Applicant(s) Msn Laboratories Limited
Representative Drug(s) D0LE6B Drug Info N.A. [2]
References  Top
REF 1 Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351.
REF 2 Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.